BioSapien

BioSapien, founded in 2018, is a pioneering company in the field of minimally invasive drug delivery platforms, specifically targeting localized cancer treatment. The company has developed a revolutionary 3D printed drug delivery chip designed to deliver medication directly to tumors, thereby minimizing the side effects often associated with systemic chemotherapy. This innovative approach has the potential to treat a wide range of lower gastrointestinal and solid tumors globally, including markets in Europe, the Middle East, and North Africa (MENA) region.

BioSapien primarily serves patients suffering from cancer, aiming to improve their quality of life through advanced, biocompatible treatments. The company operates in the healthcare and biotechnology sectors, focusing on cancer care, which saw $208.9 billion in spending in America alone in 2020. BioSapien's business model revolves around the development, manufacturing, and global distribution of its drug delivery technology. The company generates revenue through the sale of its 3D printed drug delivery chips and related medical solutions.

The company recently closed a $1.8 million seed round led by SOSV HIKMA Ventures, with additional investments from Hikma Ventures, Microventures, Infinity Capital Ventures, JPIN VCATS, Side Door Ventures, and other high net worth angels and investors. These funds will be used to advance the development of BioSapien's technology and expand its access to global distribution channels and manufacturing capabilities.

BioSapien's mission is to advance human well-being through innovative solutions, aiming to treat 1 million patients by 2035. The company's vision is to be the leader in biocompatible, minimally invasive cancer treatment, thereby transforming the healthcare landscape.

Keywords: localized cancer treatment, 3D printed chip, drug delivery, systemic chemo side effects, biocompatible, minimally invasive, healthcare innovation, biotechnology, global distribution, cancer care.